FDA Aligns on Key Endpoints for Cadrenal’s HIT Drug Trial
Event summary
- FDA agreed on primary endpoint definition for CAD-1005 Phase 3 trial in HIT, focusing on worsening thrombotic events through Day 14.
- Study will use placebo control with standard anticoagulation in both arms.
- CAD-1005 targets a $2B peak annual revenue opportunity in HIT, affecting ~50,000 U.S. patients annually.
- Type D meeting held on July 28, 2026, finalized protocol and Statistical Analysis Plan (SAP).
The big picture
The FDA’s positive feedback on CAD-1005’s Phase 3 trial design strengthens Cadrenal’s position in the orphan cardiovascular space. With no approved therapies directly targeting the immune mechanisms of HIT, CAD-1005’s success could redefine treatment paradigms for this high-stakes condition. The $2B revenue opportunity underscores the strategic importance of this alignment, particularly as biopharma investors increasingly prioritize high-impact orphan drug candidates.
What we're watching
- Regulatory Clarity
- How the FDA’s alignment on endpoints will accelerate CAD-1005’s path to approval.
- Market Potential
- Whether CAD-1005 can capture significant share in the HIT treatment space.
- Execution Risk
- The pace at which Cadrenal can initiate and complete the Phase 3 trial.